Patient Reported Experiences and Outcomes from participants’ surveys (a self-administered questionnaire) on the impact of long-term Ayahuasca ceremonies and measures of health.

Ayahuasca Survey 2017 – Patient Reported Data (OA)

Request a sample

Details

User consent

Yes

Records volume

380

Data History

2017

Data Source

✔Other | Patient Reported Data

Prevalent Dx (diagnoses)

Healthy; Unspecified

Prevalent Rx/Tx (Drug/treatment protocols)

Ayahuasca

Combined (Tx) therapy

Ceremony

Additional Data Features?

Included indicators for 8 different dimensions: General Health included measures of self-perceived health status, body mass index (BMI), presence of chronic disease, physical limitation, sleep problems, cholesterol levels, BP, medical/psych visits, and prescription drug use. Lifestyle measured physical activity, mode of work transport, & diet. Positive Mental Health included activities like yoga/meditation, feeling loved by others, vital goals, autonomy, and perception of happiness. Assessment tools used: Adjustment was measured using items from the Bell Adjustment Inventory (BAI; Bell 1962). Coping strategies were measured using items from the Coping Strategies Inventory (CSI; Tobin, Holroyd, and Reynolds 1984) and the Coping Orientation to Problems Experienced (COPE; Carver, Scheier, and Weintraub 1989). Cultural Activities included frequency of participation in activities like exhibitions, museum visits, or artistic workshops, and reading habits. Social Support measured by # of close family members & friends, the presence of someone with whom to go to the doctor, the presence of people who express affection, the possibility to share feelings of joy or sadness with a friend, and someone with whom to share private fears and worries. Personal Values dimension used the Engaged Living Scale (ELS; Trompetter et al. 2013). Open Access publications: Ayahuasca and Public Health: Health Status, Psychosocial Well-Being, Lifestyle, and Coping Strategies in a Large Sample of Ritual Ayahuasca Users(2019). Journal of Psychoactive Drugs. https://doi.org/10.1080/02791072.2019.1567961

Source

94te